Navarrete FG, Beirana PA, Bengoa IB, Champet AM, Siu CM

Language: Spanish
References: 9
Page: 92-95
PDF size: 160.26 Kb.

ABSTRACT

Gout is a systemic disorder characterized by recurrent arthritis and hyperuricemia with urate crystals deposition in synovial and nonarticular tissues. The cutaneous manifestation are subcutaneous neoformations called tophi. They occur in avascular tissue, acral sites and tendons. We present the case of a 53-year-old male with tophaceous gout.

REFERENCES

1. Becker MA. Hyperuricemia and gout. En: Scriver CR, Beaudet Al, Sly WS et al. The Metabolic and Molecular Bases of Inherited Disease, 8th edition. New York McGraw-Hill, 2001: 2154-2155.

2. Landis RC, Haskard DO. Pathogenesis of crystal-induced inflammation. Curr Rheumatol Rep 2001; 3: 36-41.

3. Kelley KN. Approach to the patient with hyperuricemia. En: Kelley WN et al. Textbook of Rheumatology, 2nd edition. Philadelphia; W.B. Saunders, 1985: 1340-1347.

4. Yu T. Diversity of clinical features in gouty arthritis. Semin Arthritis Rheum 1984; 13: 360-368.

5. Burns T, Breathnach S, Cox N, Griffiths C. Rook’s Textbook of Dermatology Vol. 4, 7th edition. Oxford: Blackwell 2004: 57: 18-19.

6. Callen J, Jorizzo J, Greer K, Penneys N, Piette WW, Zone JJ. Dermatological Signs of Internal Disease, 2nd edition. Philadelphia: WB Saunders 2000: 52-55.

7. Resave M. Allopurinol transport in human erythrocytes. Biochem Pharmacol 1993; 45: 893-897.

8. Khosravan R et al. Dose-related decreases in uric acid observed in a multiple-dose safety, pharmacokinetic, and pharmacodynamic study of TMX-67, a Novel Xanthine Oxidase/Dehydrogenase Inhibitor, in healthy subjects. ACR. Philadelphia 2000; (2009).

9. Haverstock C, Jorizzo J. Rheumatoid arthritis, rheumatic fever and gout. En: Fitzpatrick T, Eisen A, Wolff K. Dermatology in general medicine. Vol. 2, 5th edition. New York McGraw-Hill, 2005: 1575-1576.